当前位置: 首页 >> 检索结果
141. Impact of Bifurcation Lesions on Outcomes After FFR-Guided PCI or CABG.
作者: Daimy M M Dillen.;Hisao Otsuki.;Kuniaki Takahashi.;Yuhei Kobayashi.;Zsolt Piroth.;Nicolas Noiseux.;Badih El Nakadi.;Gintaras Kalinauskas.;Laszlo Szekely.;Giedrius Davidavičius.;Koen Teeuwen.;Pim A L Tonino.;Nico H J Pijls.;Bernard De Bruyne.;William F Fearon.;Frederik M Zimmermann.
来源: Circ Cardiovasc Interv. 2025年18卷1期e014610页
In the era of first-generation drug-eluting stents and angiography-guided percutaneous coronary intervention (PCI), the presence of a bifurcation lesion was associated with adverse outcomes after PCI. In contrast, the presence of a bifurcation lesion had no impact on outcomes following coronary artery bypass grafting (CABG). Therefore, the presence of a coronary bifurcation lesion requires special attention when choosing between CABG and PCI. The aim of this study is to assess whether the presence of a bifurcation lesion still influences clinical outcomes after contemporary PCI using second-generation drug-eluting stent and fractional flow reserve (FFR) guidance versus CABG.
142. Cryoballoon Pulmonary Vein Isolation With Versus Without Additional Right Atrial Linear Ablation for Persistent Atrial Fibrillation: The CRALAL Randomized Clinical Trial.
作者: Daehoon Kim.;Hee Tae Yu.;Jaemin Shim.;Junbeom Park.;Yong-Soo Baek.;Sang Won Park.;Dae-Kyeong Kim.;Young-Ah Park.;Tae-Hoon Kim.;Jae-Sun Uhm.;Boyoung Joung.;Moon-Hyoung Lee.;Hui-Nam Pak.
来源: Circ Arrhythm Electrophysiol. 2025年18卷1期e013408页
Pulmonary vein isolation (PVI) alone is less effective in patients with persistent atrial fibrillation (AF) compared with those with paroxysmal AF. We investigate whether additional linear ablation from the superior vena cava to the right atrial septum and cavotricuspid isthmus ablation improves the rhythm outcome of patients with persistent AF undergoing cryoballoon PVI (Cryo-PVI).
143. Nurse-Led Multicomponent Behavioral Activation Intervention for Patients With Atrial Fibrillation: A Randomized Controlled Trial.
Patients with atrial fibrillation (AF) are often ill-equipped for shared decision-making. This study investigated the effects of a patient empowerment care model on patient-reported health outcomes and treatment decision-making in patients with AF.
144. Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial.
作者: Harmony R Reynolds.;Courtney B Page.;Leslee J Shaw.;Daniel S Berman.;Bernard R Chaitman.;Michael H Picard.;Raymond Y Kwong.;James K Min.;Jonathon Leipsic.;G B John Mancini.;Matthew J Budoff.;Cameron J Hague.;Roxy Senior.;Hanna Szwed.;Balram Bhargava.;Jelena Celutkiene.;Milind Gadkari.;Kevin R Bainey.;Rolf Doerr.;Ruben B Ramos.;Peter Ong.;Sudhir R Naik.;Philippe Gabriel Steg.;Kaatje Goetschalckx.;Benjamin J W Chow.;Marielle Scherrer-Crosbie.;Lawrence Phillips.;Daniel B Mark.;John A Spertus.;Karen P Alexander.;Sean M O'Brien.;William E Boden.;Sripal Bangalore.;Gregg W Stone.;David J Maron.;Judith S Hochman.; .
来源: Circ Cardiovasc Interv. 2024年17卷12期e013743页
The relationship between the extent and severity of stress-induced ischemia and the extent and severity of anatomic coronary artery disease (CAD) in patients with obstructive CAD is multifactorial and includes the intensity of stress achieved, type of testing used, presence and extent of prior infarction, collateral blood flow, plaque characteristics, microvascular disease, coronary vasomotor tone, and genetic factors. Among chronic coronary disease participants with site-determined moderate or severe ischemia, we investigated associations between ischemia severity on stress testing and the extent of CAD on coronary computed tomography angiography.
145. Superior Vena Cava Isolation With Cryoballoon in AF Ablation: Randomized CAVAC AF Trial.
作者: Víctor Castro-Urda.;Melodie Segura-Dominguez.;Diego Jiménez-Sánchez.;Cristina Aguilera-Agudo.;Paula Vela-Martín.;Alvaro Lorente-Ros.;Daniel García-Rodriguez.;David Sánchez-Ortiz.;Chinh Pham-Trung.;Eusebio García-Izquierdo.;Susana Mingo-Santos.;Jorge Toquero-Ramos.;Ignacio Fernández-Lozano.
来源: Circ Arrhythm Electrophysiol. 2025年18卷1期e012917页
Superior vena cava (SVC) has been considered a specific trigger in atrial fibrillation development.
146. Inappropriate Therapy and Shock Rates Between the Subcutaneous and Transvenous Implantable Cardiac Defibrillator: A Secondary Analysis of the PRAETORIAN Trial.
作者: Louise R A Olde Nordkamp.;Shari Pepplinkhuizen.;Abdul Ghani.;Lucas V A Boersma.;Juergen Kuschyk.;Mikhael F El-Chami.;Elijah R Behr.;Tom F Brouwer.;Stefan Kääb.;Suneet Mittal.;Anne-Floor B E Quast.;Willeke van der Stuijt.;Lonneke Smeding.;Jolien A de Veld.;Jan G P Tijssen.;Nick R Bijsterveld.;Sergio Richter.;Marc A Brouwer.;Joris R de Groot.;Kirsten M Kooiman.;Pier D Lambiase.;Petr Neuzil.;Kevin Vernooy.;Marco Alings.;Timothy R Betts.;Frank A L E Bracke.;Martin C Burke.;Jonas S S G de Jong.;David J Wright.;Ward P J Jansen.;Zachary I Whinnett.;Peter Nordbeck.;Michael Knaut.;Berit T Philbert.;Jurren M van Opstal.;Alexandru B Chicos.;Cornelis P Allaart.;Alida E Borger van der Burg.;Jose M Dizon.;Marc A Miller.;Dmitry Nemirovsky.;Ralf Surber.;Gaurav A Upadhyay.;Raul Weiss.;Anouk de Weger.;Arthur A M Wilde.;Reinoud E Knops.; .
来源: Circ Arrhythm Electrophysiol. 2024年17卷12期e012836页
Inappropriate therapy (IAT) is an undesirable side effect of implantable cardiac defibrillator (ICD) therapy. Early studies with the subcutaneous ICD (S-ICD) showed relatively high inappropriate shock (IAS) rates. The PRAETORIAN (Prospective Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) trial demonstrated that the S-ICD is noninferior to the transvenous ICD (TV-ICD) with regard to the combined end point of IAS and complications. This secondary analyses evaluates all IAT in the PRAETORIAN trial.
147. Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF).
作者: Neal W Dickert.;Candace D Speight.;Madeline Balser.;Henry Biermann.;J Kelly Davis.;Scott D Halpern.;Yi-An Ko.;Advaita Krishnan.;Daniel D Matlock.;Andrea R Mitchell.;Miranda A Moore.;Sarah C Montembeau.;Alanna A Morris.;Kathleen Noonan.;Birju R Rao.;Laura D Scherer.;Caroline E Sloan.;Peter A Ubel.;Larry A Allen.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷1期e011273页
Guideline-directed medical therapy for heart failure (HF) with reduced ejection fraction can entail high out-of-pocket (OOP) costs, prompting concerns about financial toxicity and access. OOP costs are generally unavailable during encounters. This trial assessed the impact of providing patient-specific OOP costs to patients and clinicians.
148. Comparison of Procedural Outcomes of Lumenless Fixed-Helix Versus Stylet-Driven Extendable-Helix Lead Systems in Left Bundle Branch Pacing: COMPARE LBBP.
作者: Jenish P Shroff.;Anugrah Nair.;Deep Chandh Raja.;Sreevilasam P Abhilash.;Simon Fiorese.;Jonathan P Ariyaratnam.;Walter P Abhayaratna.;Prashanthan Sanders.;Pugazhendhi Vijayaraman.;Rajeev K Pathak.
来源: Circ Arrhythm Electrophysiol. 2024年17卷12期e013385页
Left bundle branch pacing (LBBP) has emerged as a safe and effective alternative to right ventricular pacing. Traditionally, LBBP is performed with lumenless lead (LLL); however, the use of stylet-driven lead (SDL) is on rise. We aimed to assess acute success and procedural outcomes of SDL versus LLL for LBBP.
149. CTCA Prior to Invasive Coronary Angiography in Patients With Previous Bypass Surgery: Patient-Related Outcomes, Imaging Resource Utilization, and Cardiac Events at 3 Years From the BYPASS-CTCA Trial.
作者: Matthew Kelham.;Anne-Marie Beirne.;Krishnaraj S Rathod.;Mervyn Andiapen.;Lucinda Wynne.;Annastazia E Learoyd.;Nasim Forooghi.;Rohini Ramaseshan.;James C Moon.;Ceri Davies.;Christos V Bourantas.;Andreas Baumbach.;Charlotte Manisty.;Andrew Wragg.;Amrita Ahluwalia.;Francesca Pugliese.;Anthony Mathur.;Daniel A Jones.
来源: Circ Cardiovasc Interv. 2024年17卷12期e014142页
In patients with previous coronary artery bypass grafting, computed tomography cardiac angiography (CTCA) before invasive coronary angiography (ICA) was demonstrated in the BYPASS-CTCA trial (Randomized Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients) to reduce procedure time and incidence of contrast-associated acute kidney injury, with greater levels of patient satisfaction. Patient-related outcomes, utilization of further diagnostic imaging resources, and longer-term incidence of major adverse cardiac events were key secondary end points not yet reported.
150. Quantifying Pill Disutility Associated With Starting Versus Continuing Cardioprotective Medication: A Randomized Experiment.
作者: Alexander Chaitoff.;Julie C Lauffenburger.;Nancy Haff.;Katharina Tabea Jungo.;Niteesh K Choudhry.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷11期e011069页
Quantifying patient-reported pill disutility is important for understanding the risk-benefit tradeoffs of taking medications. The objective of this study was to quantify and compare the pill disutility associated with starting a new medication and continuing an existing medication for cardiometabolic disease prevention in a sample of older adults in the United States.
151. Quality of Life in Subcutaneous or Transvenous Implantable Cardioverter-Defibrillator Patients: A Secondary Analysis of the PRAETORIAN Trial.
作者: Reinoud E Knops.;Jolien A de Veld.;Abdul Ghani.;Lucas V A Boersma.;Juergen Kuschyk.;Mikhael F El Chami.;Hendrik Bonnemeier.;Elijah R Behr.;Tom F Brouwer.;Stefan Kääb.;Suneet Mittal.;Shari Pepplinkhuizen.;Anne-Floor B E Quast.;Lonneke Smeding.;Willeke van der Stuijt.;Anouk de Weger.;Nick R Bijsterveld.;Sergio Richter.;Marc A Brouwer.;Joris R de Groot.;Kirsten M Kooiman.;Pier D Lambiase.;Petr Neuzil.;Kevin Vernooy.;Marco Alings.;Timothy R Betts.;Frank A L E Bracke.;Martin C Burke.;Jonas S S G de Jong.;David J Wright.;Ward P J Jansen.;Zachary I Whinnett.;Peter Nordbeck.;Michael Knaut.;Berit T Philbert.;Jurren M van Opstal.;Alexandru B Chicos.;Cornelis P Allaart.;Alida E Borger van der Burg.;Jose M Dizon.;Marc A Miller.;Dmitry Nemirovksy.;Ralf Surber.;Gaurav A Upadhyay.;Jan G P Tijssen.;Arthur A M Wilde.;Louise R A Olde Nordkamp.; .
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷11期e010822页
The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to overcome the risk of lead-related complications associated with the transvenous implantable cardioverter-defibrillator (TV-ICD). In contrast to the TV-ICD, the S-ICD is a completely extrathoracic device. Subsequently, complications differ between these 2 implantable cardioverter-defibrillators, which might impact patient perceptions of the therapies. This prespecified secondary analysis of the PRAETORIAN trial evaluates differences in quality of life.
152. Association of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.
作者: Konstantinos C Koskinas.;Jonas Häner.;Yasushi Ueki.;Tatsuhiko Otsuka.;Jacob Lonborg.;Hiroki Shibutani.;Ryota Kakizaki.;Christoph Kaiser.;Robert-Jan van Geuns.;Anna S Ondracek.;Fabien Praz.;Maria Ambühl.;David Spirk.;Jonas Lanz.;Joost Daemen.;Dik Heg.;Manuel Mayr.;François Mach.;Stephan Windecker.;Thomas Engstrøm.;Irene M Lang.;Arnold von Eckardstein.;Sylvain Losdat.;Lorenz Räber.
来源: Circ Cardiovasc Imaging. 2024年17卷11期e016683页
Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy.
153. Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.
作者: Michael R Zile.;Barry A Borlaug.;Christopher M Kramer.;Seth J Baum.;Sheldon E Litwin.;Venu Menon.;Yang Ou.;Govinda J Weerakkody.;Karla C Hurt.;Chisom Kanu.;Masahiro Murakami.;Milton Packer.; .
来源: Circulation. 2025年151卷10期656-668页
Patients with heart failure with preserved ejection fraction and obesity have significant disability and frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical end points, including measures of health status, functional capacity, quality of life, exercise tolerance, patient well-being, and medication burden, in these patients.
154. Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
作者: Daniel P Judge.;Julian D Gillmore.;Kevin M Alexander.;Amrut V Ambardekar.;Francesco Cappelli.;Marianna Fontana.;Pablo García-Pavía.;Justin L Grodin.;Martha Grogan.;Mazen Hanna.;Ahmad Masri.;Jose Nativi-Nicolau.;Laura Obici.;Steen Hvitfeldt Poulsen.;Nitasha Sarswat.;Keyur Shah.;Prem Soman.;Ted Lystig.;Xiaofan Cao.;Kevin Wang.;Maria Lucia Pecoraro.;Jean-François Tamby.;Leonid Katz.;Uma Sinha.;Jonathan C Fox.;Mathew S Maurer.
来源: Circulation. 2025年151卷9期601-611页
In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE.
155. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM.
作者: Milind Y Desai.;Kathy Wolski.;Anjali Owens.;Jeffrey B Geske.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Paul C Cremer.;Neal K Lakdawala.;Albree Tower-Rader.;David Fermin.;Srihari S Naidu.;Nicholas G Smedira.;Hartzell Schaff.;Zhiqun Gong.;Lana Mudarris.;Kathy Lampl.;Amy J Sehnert.;Steven E Nissen.; .
来源: Circulation. 2025年151卷19期1378-1390页
In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128.
156. Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
作者: Yugo Yamashita.;Takeshi Morimoto.;Nao Muraoka.;Wataru Shioyama.;Ryuki Chatani.;Tatsuhiro Shibata.;Yuji Nishimoto.;Yoshito Ogihara.;Kosuke Doi.;Maki Oi.;Taro Shiga.;Daisuke Sueta.;Kitae Kim.;Yasuhiro Tanabe.;Norimichi Koitabashi.;Takuma Takada.;Satoshi Ikeda.;Hitoshi Nakagawa.;Kengo Tsukahara.;Masaaki Shoji.;Jiro Sakamoto.;Shinji Hisatake.;Yutaka Ogino.;Masashi Fujita.;Naohiko Nakanishi.;Tomohiro Dohke.;Seiichi Hiramori.;Ryuzo Nawada.;Kazuhisa Kaneda.;Koh Ono.;Takeshi Kimura.; .
来源: Circulation. 2025年151卷9期589-600页
The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding.
157. Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial.
作者: Scott A Hubers.;Sherry L Benike.;Bradley K Johnson.;Paul M McKie.;Christopher Scott.;Horng H Chen.
来源: Circ Heart Fail. 2024年17卷12期e011761页
Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF.
158. Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial.
作者: Helga Lillian Gudmundsdottir.;Anna Axelsson Raja.;Kasper Rossing.;Hanne Rasmusen.;Martin Snoer.;Lars Juel Andersen.;Rikke Gottlieb.;Alex Hørby Christensen.;Henning Bundgaard.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷2期132-144页
Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience reduced exercise capacity. Physical training improves exercise capacity in these patients, but whether the underlying effects of exercise are a result of central hemodynamic or peripheral improvement is unclear. This study assessed whether exercise training reduces left ventricular filling pressure measured during exercise in patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction.
159. Relative Benefit of Dual Versus Single Antiplatelet Therapy Among Patients With Atrial Fibrillation on Oral Anticoagulation According to Time After ACS and PCI: Insights From the AUGUSTUS Trial.
作者: Alexander C Fanaroff.;Daniel M Wojdyla.;Christopher B Granger.;Shaun G Goodman.;Ronald S Aronson.;Stephan Windecker.;Roxana Mehran.;John H Alexander.;Renato D Lopes.
来源: Circ Cardiovasc Interv. 2024年17卷11期e013596页
In the AUGUSTUS trial (An Open-Label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), the combination of dual antiplatelet therapy plus oral anticoagulation increased the risk of bleeding without reducing ischemic events compared with a P2Y12 inhibitor plus oral anticoagulation among patients with atrial fibrillation and acute coronary syndrome or elective percutaneous coronary intervention. However, AUGUSTUS enrolled patients up to 14 days after acute coronary syndrome or percutaneous coronary intervention, and there may be a benefit to dual antiplatelet therapy plus oral anticoagulation early after an ischemic event.
160. Impact of a Chronic Total Occlusion on Outcomes After FFR-Guided PCI or Coronary Bypass Surgery: A FAME 3 Substudy.
作者: Hisao Otsuki.;Kuniaki Takahashi.;Frederik M Zimmermann.;Kreton Mavromatis.;Adel Aminian.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Philip MacCarthy.;Nils Witt.;Yuhei Kobayashi.;Tatsunori Takahashi.;Y Joseph Woo.;Alan C Yeung.;Bernard De Bruyne.;Nico H J Pijls.;William F Fearon.; .
来源: Circ Cardiovasc Interv. 2024年17卷11期e014300页
The clinical impact of a chronic total occlusion (CTO) in patients with 3-vessel coronary artery disease undergoing fractional flow reserve-guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents or coronary artery bypass grafting (CABG) is unclear.
|